Building a pipeline of Innovative, highly targeted single-domain antibody based therapies to serve patients
Events & Presentations
Selected to present at BioLabs NYU Langone Investor & Innovator Exchange, Kimmel Pavillion, June 10, 2024
Selected to present at NJADDC Symposium, Princeton University, November 16, 2023
Selected to present poster at BioLabs Philadelphia Investor Day, Curtis Building, April 16, 2024
Selected to present at the International Cancer Cluster Showcase at BIO 2023, Boston Convention & Exhibit Center on June 5, 2023
Selected to present at BioLabs Philadelphia Investor Day, Curtis Building, April 27, 2023
Presentation at BioFuture, in New York City on November 8, 2022.
News & Media
A high affinity and specificity anti-her2 single-domain antibody (VHH) that targets trastuzumab’s epitope
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope with versatile biochemical, biological, and medical applications – PubMed (nih.gov)https://pubmed.ncbi.nlm.nih.gov/37632647/
Research into novel BiKE:HER2/CD16a nanobody published in Frontiers in Immunology
Research into novel BiKE:HER2/CD16a nanobody published in Frontiers in Immunology Arash Hatefi, PharmD, PhD, Professor, Department of Pharmaceutics at Rutgers’ Ernest Mario School of Pharmacy
Sauvie Inc. Enters into an Exclusive Worldwide License Agreement to Develop and Commercialize a Nanobody-based NK Cell Engager
SHORT HILLS, N.J., Oct. 24, 2022/PRNewswire/ – Sauvie Inc. (the “Company”), a mission-driven biopharmaceutical company focused on sustainably building an immuno-oncology company, today announced Sauvie’s subsidiary, Sauvie BiKE LLC, has entered into an exclusive license agreement with Rutgers, The State University of New Jersey (“Rutgers”) for the development and worldwide commercialization rights of a bi-specific natural killer (NK) cell engager technology in the field of oncology.
